![]() |
|
Names | |
---|---|
IUPAC names
4-Phenoxyphenyl (R/S)-2-(2-pyridyloxy)propyl ether
2-[1-(4-Phenoxyphenoxy)propan-2-yloxy]pyridine |
|
Identifiers | |
3D model (JSmol)
|
|
ChEBI | |
ChemSpider | |
ECHA InfoCard | 100.102.814 |
KEGG | |
PubChem CID
|
|
UNII | |
|
|
|
|
Properties | |
C20H19NO3 | |
Molar mass | 321.38 g·mol−1 |
Appearance | Colorless crystals |
Density | 1.2 g/cm3 |
Melting point | 48–50 °C (118–122 °F; 321–323 K) |
Boiling point | 318 °C (604 °F; 591 K) |
0.367 mg/L | |
Pharmacology | |
QP53AX23 (WHO) | |
Except where otherwise noted, data are given for materials in their standard state (at 25 °C [77 °F], 100 kPa).
|
|
![]() ![]() ![]() |
|
Infobox references | |
Pyriproxyfen is a pyridine-based pesticide which is found to be effective against a variety of arthropoda. It was introduced to the US in 1996, to protect cotton crops against whitefly. It has also been found useful for protecting other crops. It is also used as a prevention for flea control on household pets, for killing indoor and outdoor ants and roaches. Methods of application include aerosols, bait, carpet powders, foggers, shampoos and pet collars.
Pyriproxyfen is a juvenile hormone analog and an insect growth regulator. It prevents larvae from developing into adulthood and thus rendering them unable to reproduce.
In the US, pyriproxyfen is often marketed under the trade name Nylar. In Europe, pyriproxyfen is known under the brand names Cyclio (Virbac) and Exil Flea Free TwinSpot (Emax).
Pyriproxyfen has low acute toxicity. According to WHO and FAO, at elevated doses exceeding 5000 mg/kg of body weight, pyriproxyfen affects the liver in mice, rats and dogs. It also changes cholesterol levels, and may cause modest anemia at high doses.
Starting in 2014, pyriproxifen was put into Brazilian water supplies to fight the proliferation of mosquito larvae. This is in line with the World Health Organization (WHO)'s Pesticide Evaluation Scheme (WHOPES) for larvicides. In January 2016, the Brazilian Association for Collective Health (Abrasco; Portuguese: Associação Brasileira de Saúde Coletiva) criticized the introduction of pyriproxyfen in Brazil. Abrasco demanded the "immediate suspension of [use of] pyriproxyfen and all growth inhibitors ... in drinking water." The organization is opposed to the use of growth inhibitors in the context of an ongoing outbreak of fetal malformation.